Cipher Pharma out-licenses rights to ASF-1096 to Edesa Biotech

Cipher Pharmaceuticals (TSX: CPH) has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders to fellow Canada-based Edesa Biotech

ASF-1096 is a Phase II product candidate that Cipher is investigating as a treatment for selected inflammatory skin disorders. Cipher acquired the global rights to the product in February 2015. Under this agreement, Cipher retains all rights to ASF-1096 for dermatological conditions. Specific terms of the agreement were not disclosed.

ASF-1096 is the first dermatological agent selectively targeting the β2-adrenoceptor of dermal inflammatory cells including keratinocytes and various infiltrating leukocytes. When applied topically, ASF-1096 penetrates through the stratum corneum and binds to β2-adrenoceptors, leading to immunomodulatory effects by reducing inflammatory reactions mediated by CD4+ lymphocytes and other types of β2-adrenoceptor presenting leukocytes. This results in a decrease of pro-inflammatory gene products such as IL-2, TNF-α, and IFN-γ. ASF-1096 was granted Orphan Drug Status by the European Medicines Agency for the treatment of cutaneous forms of Lupus Erythematosus.